Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Beta-blockers, alpha-blockers, central sympatholytics, and direct vasodilators
6 evidence topics · 4 sources
Fourth- and fifth-line alternatives: 2025 AHA/ACC guideline
Beta-blockers as secondary agents: 2025 AHA/ACC guideline
Alpha-1 blockers, central agents, and direct vasodilators: 2025 AHA/ACC guideline drug table
Order of alternative agents: 2024 ESC guideline
Alternatives when mineralocorticoid receptor antagonists are not tolerated: 2023 ESH guideline
Spironolactone versus clonidine as the fourth drug: ReHOT trial
“Patients with resistant hypertension (no office and ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with spironolactone (12.5-50 mg QD) or clonidine (0.1-0.3 mg BID).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote